Sitagliptin Base Composition Micronization Solubility Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutical compositions of sitagliptin that enhance solubility, stability, bioavailability, and storage stability, while maintaining bioequivalence to existing sitagliptin phosphate monohydrate formulations like Januvia®, which are used to treat type 2 diabetes mellitus.
Innovation Solution
A stable pharmaceutical composition of sitagliptin in its base form, combined with beneficial agents such as alginic acid, cyclodextrins, or surfactants, which are micronized to improve solubility and stability, and formulated with pharmaceutically acceptable excipients to ensure consistent absorption and storage stability, achieving a bioequivalent profile to Januvia®.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If sitagliptin phosphate monohydrate is used as the active pharmaceutical ingredient, then the composition can be formulated for oral administration, but the solubility and bioavailability are limited
Solution Approach 1:
The patent changes the chemical form of sitagliptin from phosphate salt to base form, and utilizes micronization to alter particle size parameters. This fundamentally changes the dissolution characteristics and bioavailability profile of the drug substance
Solution Approach 2:
The patent creates a composite formulation by combining micronized sitagliptin base with specific excipients including alginic acid, cyclodextrins, and surfactants. This composite approach enhances solubility through multiple mechanisms acting synergistically
2Ease of manufacture
If sitagliptin phosphate monohydrate formulations are used, then the composition can be manufactured, but the storage stability deteriorates under accelerated conditions
Solution Approach 1:
The patent changes the chemical form from phosphate salt to base form and reduces particle size through micronization, which fundamentally alters the stability profile of the drug substance under various storage conditions
Solution Approach 2:
The patent introduces alginic acid as a stabilizing excipient that acts as an intermediary between the drug substance and environmental factors. This excipient protects the micronized sitagliptin base from degradation during storage
3Quantity of substance
If sitagliptin is micronized to improve solubility, then the bioavailability increases, but the manufacturing complexity increases
Solution Approach 1:
The patent performs micronization as a preliminary step during drug substance manufacturing, creating a stable micronized powder that can be directly used in formulation without requiring additional size reduction equipment during tablet manufacturing
Solution Approach 2:
The patent establishes specific micronization parameters (particle size range) that optimize both solubility enhancement and manufacturability, creating a balance between improved bioavailability and practical manufacturing considerations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition demonstrates enhanced stability and bioavailability, maintaining at least 90% potency after three months at 40°C and 75% relative humidity, with a plasma profile comparable to Januvia®, ensuring effective treatment of type 2 diabetes mellitus.
Implementation Method 1
combined with beneficial agents such as alginic acid, cyclodextrins, or surfactants
Implementation Method 2
enhance solubility, stability, bioavailability
Implementation Method 3
which are micronized to improve solubility and stability
Implementation Method 4
maintaining at least 90% potency after three months at 40°C and 75% relative humidity
Data Source
AI summary
The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.